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Abstract.
BACKGROUND: Sickle cell anemia (SCA) is an inherited blood disorder. SCA patients present clinical and hematologic
variability that cannot be only explained by the single mutation in the beta-globin gene. Others genetic modifiers and
environmental effects are important for the clinical phenotype. SCA patients present arginine deficiency that contributes to
a lower nitric oxide (NO) bioactivity.
OBJECTIVE: The aim of this work is to determine the association between hematological and biochemical parameters and
genetic variants from eNOS gene, in pediatric SCA patients.
METHODS: 26 pediatric SCA patients were genotyped using polymerase chain reaction (PCR) and restriction fragment
length polymorphism (RFLP) techniques in three important eNOS gene polymorphisms - rs2070744, rs1799983 and intron
4 VNTR.
RESULTS: Results from this study show a significant statistical association between some parameters and genetic variants:
an increased reticulocyte count and high serum lactate dehydrogenase levels were associated with both the rs2070744 TT
and the rs1799983 GG genotypes at eNOS gene and high levels of neutrophils were associated with the eNOS4a allele at
intron 4 VNTR.
CONCLUSIONS: Our results reinforce the importance of NO bioactivity in SCA. We presume that NO, and its precursors
might be used as therapy to improve the quality of life of SCA patients.
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1. Introduction
Sickle cell anemia (SCA) is an autosomal recessive hereditary anemia characterized by the presence
of hemoglobin S (Hb S) and is one of the most common human genetic disorders world-wide [20], This
disease is caused by a single point mutation in the beta-globin gene, located on chromosome 11, with
a corresponding amino acid substitution at the sixth position of the beta-globin chain [10]. Hemolytic
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anemia and vaso-occlusion are the major features of this disease. Red blood cell rheology and adhesive-
ness play a key role in the occurrence of vaso-occlusive like events in sickle cell anemia, with stiffness
of sickle erythrocytes and topography of cell membrane affecting adhesion to the endothelium [2].
SCA patients present clinical and hematologic variability that cannot be only explained by the single
mutation in the beta-globin gene. Others genetic modifiers and environmental effects are important
in the clinical phenotype [18]. Nitric oxide (NO), a gas with potent vasodilation, antiadhesive and
antioxidative properties, represents a critical molecule for proper endothelial function and maintenance
of a patent vascular lumen [7, 17]. A study shows that systemic vascular resistance in SCA is positively
correlated with red blood cell deformability, and negatively with nitric oxide metabolites level in SCA
children [12]. The endothelial NO synthase (eNOS), an enzyme that generates NO, is expressed in the
endothelium, encoded by a gene (eNOS) located on chromosome 7 [19]. A recent study found that
red blood cell nitric oxide synthase modulates red blood cell deformability in SCA [14]. SCA patients
present endothelial dysfunction due to impaired bioavailability of endogenous nitric oxide caused by
scavenging of NO by cell-free plasma hemoglobin and consumption of L-arginine amino acid by
cell-free arginase enzyme released from hemolyzed red blood cell [24]. Several polymorphic variants
have been described in the eNOS gene [6]. The present study aims to explore the association between
hematological and biochemical parameters with genetic variants from eNOS gene, in pediatric SCA
patients.
2. Patients and methods
2.1. Patients
We investigated 26 patients with SCA (18 males and 8 females) followed up in Hospital de Dona
Estefaˆnia, in Lisbon. Their age ranged from 3 to 19 years with a mean of 8.58 ± 5.25 years. An informed
consent was obtained from the guardian of each patient before participation. This study was approved
by the University of Lisbon’s Committee on Ethics.
2.2. Phenotypic characterization
Hb S, total Hb, red cell distribution width (RDW), levels of leukocytes, levels of neutrophils, serum
lactate dehydrogenase (LDH), total bilirubin and reticulocyte count were collected from the patients’
hospital records and these parameters were obtained during the steady-state periods. Acid phosphatase
(ACP1) enzymatic activity was determined in erythrocytes as described by Dissing, Dahl e Svansmark
[9]. Transmembrane reductase (TMR) was performed using an adapted method modified by Orringer
and Roer [15]. Methemoglobin reductase (MetHbR) was determined using an adapted method modified
by Board & Pidcock [3]. Myeloperoxidase (MPO) was determined by ELISA (R&D Systems Inc.).
2.3. Genotyping
Amplification of DNA samples for polymorphic analysis of variable number of tandem repeats
(VNTR) in intron 4 (27 bp tandem repeat) was performed by polymerase chain reaction (PCR). Amplifi-
cation of DNA samples for polymorphic analysis of single nucleotide polymorphism (SNP) rs2070744
and SNP rs1799983 were performed by PCR followed by restriction fragment length analysis. Adher-
ence to the Hardy-Weinberg equilibrium constant was confirmed. The homozygous status for the SCA
mutation (HBB:c.20A>T) was confirmed by PCR followed by Bsu36I restriction fragment length
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2.4. Statistical analysis
Association studies were performed using T test/ ANOVA parametric tests (Hb S, total Hb,
RDW, levels of neutrophils, ACP1, TMR, MetHbR, MPO and reticulocyte count) or Mann-Whitney/
Kuskal-Wallis non-parametric tests (levels of leukocytes, LDH and total bilirubin). eNOS gene haplo-
types were estimated. All tests were performed with SPSS 22.0 software. Statistical significance was
defined as a P-value < 0.05.
3. Results
Polymorphisms analyzed for the eNOS gene are: the variable number of tandem repeats in intron
4, eNOS 4a/b; a SNP in the promoter region, rs2070744; and another in exon 7, rs1799983. Results
from this study show a significant statistical association between some parameters and genetic variants
at eNOS gene. An increased reticulocyte count and high LDH levels were associated with both the
rs2070744 TT (Table 1 and Fig. 1) and the rs1799983 GG genotypes (Table 2 and Fig. 2) and high
levels of neutrophils were associated with the eNOS4a allele at intron 4 VNTR (Table 3 and Fig. 3).
Rs2070744 CC was not found in the population. There is no significant difference between the other
parameters and genetic variants/ haplotypes at eNOS gene (Tables 1, 2, 3 and 4).
4. Discussion
Sickle cell anemia is one of the most common human genetic disorders world-wide and represents
a major public health problem. Considering the unusual clinical heterogeneity, it is imperative that the
significance of polymorphisms with clinical relevance be delineated.
In this study we analyzed three well-characterized polymorphisms: intron 4 (27 bp VNTR),
rs2070744 (–786TC) and rs1799983 (Glu298Asp). Results showed a significant statistical association
between commonly measured hemolysis biomarkers and two of the eNOS polymorphisms, an increased
reticulocyte count and high LDH levels were associated with both, the rs2070744 TT (Table 1 and
Fig. 1) and the rs1799983 GG (Table 2 and Fig. 2) genotypes at eNOS gene. Concerning rs2070744 TT,
Table 1
Association between hematological and biochemical parameters and rs2070744 genotypes (TT and CT) at eNOS gene
Parameters TT CT p-value
Total Hb (g/dL) 8.23 ± 1.20 (13) 9.14 ± 1.28 (10) 0.0951
Hb S (%) 76.26 ± 6.08 (12) 73.06 ± 7.11 (10) 0.2681
Total bilirubin (mg/dL) 1.74; 1.26–2.80 (7) 2.00; 1.30–5.57 (5) 0.5302
LDH (U/L) 490.00; 410.00–793.00 (7) 371.50; 328.00–451.00 (4) 0.0422
RDW (%) 22.53 ± 1.93 (7) 20.73 ± 3.12 (3) 0.2881
Reticulocyte count (%) 9.56 ± 3.43 (13) 6.12 ± 2.50 (10) 0.0151
Levels of leukocytes (cell/L) 12300.00; 7000.00–33100.00 (7) 10400.00; 10200.00–10500.00 (3) 0.6672
Levels of neutrophils (cell/L) 5287.86 ± 2339.76 (7) 4666.67 ± 1776.30 (3) 0.6951
ACP1 (mol/g Hb/h) 357.26 ± 57.00 (7) 379.95 ± 146.08 (7) 0.7121
MPO (ng/mL) 38.98 ± 20.17 (8) 35.40 ± 17.86 (6) 0.7371
MetHbR (mol/g Hb/min) 27.39 ± 12.13 (6) 21.02 ± 5.80 (7) 0.2401
TMR (mmol/lcell/h) 4.90 ± 0.27 (2) 5.43 ± 1.73 (2) 0.7111
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Fig. 1. Box plots of the distribution of reticulocyte count (a) and LDH level (b) in rs2070744 genotypes (TT and CT) at eNOS
gene.
Table 2
Association between hematological and biochemical parameters and rs1799983 genotypes (GG and GT/TT) at eNOS gene
Parameters GG GT ou TT p-value
Total Hb (g/dL) 8.46 ± 1.18 (17) 9.02 ± 1.77 (5) 0.4121
Hb S (%) 75.04 ± 6.40 (16) 76.46 ± 5.99 (5) 0.6651
Total bilirubin (mg/dL) 1.70; 1.26–2.80 (8) 3.73; 1.40–5.57 (4) 0.1542
LDH (U/L) 490.00; 410.00–793.00 (7) 371.50; 328.00–451.00 (4) 0.0422
RDW (%) 21.86 ± 2.59 (8) 22.50 ± 0.85 (2) 0.7501
Reticulocyte count (%) 9.20 ± 3.21 (17) 4.53 ± 1.75 (5) 0.0061
Levels of leukocytes (cell/L) 11250.00; 7000.00–33100.00 (8) 10450.00; 10400.00–10500.00 (2) 1.0002
Levels of neutrophils (cell/L) 5010.63 ± 2303.76 (8) 5465.00 ± 1576.85 (2) 0.8031
ACP1 (mol/g Hb/h) 339.82 ± 72.23 (8) 438.45 ± 130.03 (5) 0.1031
MPO (ng/mL) 40.09 ± 19.16 (9) 32.69 ± 18.53 (5) 0.4981
MetHbR (mol/g Hb/min) 26.04 ± 11.64 (7) 23.36 ± 4.75 (5) 0.6401
TMR (mmol/lcell/h) 4.90 ± 0.27 (2) 5.43 ± 1.78 (2) 0.7111
1T test - Mean ± standard deviation (n – sample size). 2Mann-Whitney test - Median; minimum - maximum (n – sample size).
results are not unexpected since the corresponding T allele in the promoter region was already reported
associated with lower levels of gene expression [22]. Our results confirm once more a functional effect
of this polymorphism on eNOS gene. Regarding the other polymorphism (rs1799983), its effect is still
controversial since the aspartate substitution at 298 does not seem to have a major effect in modulating
eNOS activity in vivo [21], however an association of the T allele with pre-eclampsia [11] and ischemic
heart disease [5] was reported strengthening the importance of this polymorphism. Studies with intron
4 VNTR polymorphism revealed an association between the 4a allele with coronary heart disease
[16] and renal disease [4, 23]. Another study found that eNOS intron 4 VNTR gene polymorphism is
related to endothelial dysfunction and vasculopathy in sickle cell disease [19]. As modulators of the
inflammatory response, neutrophils are in high number in SCA patients. In this study higher number
of neutrophils were associated with the eNOS4a allele (Table 3 and Fig. 3). NO exerts regulatory
effects on neutrophil, with low concentrations being stimulatory [1, 8]. A study showed that levels of
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Fig. 2. Box plots of the distribution of reticulocyte count (a) and LDH level (b) in rs1799983 genotypes (GG and GT/TT) at
eNOS gene.
Table 3
Association between hematological and biochemical parameters and the presence or absence of eNOS4a allele at eNOS gene
Parameters Presence of 4a allele Absence of 4a allele p-value
Total Hb (g/dL) 8.26 ± 1.01 (13) 9.10 ± 1.51 (10) 0.1251
Hb S (%) 76.16 ± 6.58 (12) 73.18 ± 6.59 (10) 0.3041
Total bilirubin (mg/dL) 1.74; 1.30–2.80 (7) 2.00; 1.26–5.57 (5) 0.5302
LDH (U/L) 477.50; 411.00–793.00 (6) 410.00; 328.00–516.00 (5) 0.1262
RDW (%) 22.28 ± 2.69 (7) 21.30 ± 1.21 (3) 0.5701
Reticulocyte count (%) 8.68 ± 3.50 (13) 7.27 ± 3.43 (10) 0.3461
Levels of leukocytes (cell/L) 12300.00; 9800.00–33100.00 (7) 10200.00; 7000.00–10400.00 (3) 0.1172
Levels of neutrophils (cell/L) 5942.14 ± 1800.85 (7) 3140.00 ± 1417.78 (3) 0.0451
ACP1 (mol/g Hb/h) 377.90 ± 122.59 (8) 356.20 ± 92.20 (6) 0.7231
MPO (ng/mL) 40.43 ± 20.06 (9) 32.07 ± 16.14 (5) 0.4421
MetHbR (mol/g Hb/min) 25.88 ± 11.08 (8) 20.88 ± 5.73 (5) 0.3751
TMR (mmol/lcell/h) 4.64 ± 0.62 (2) 5.68 ± 1.37 (2) 0.4361
1T test - Mean ± standard deviation (n – sample size). 2Mann-Whitney test - Median; minimum - maximum (n – sample size).
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Table 4
Association between hematological and biochemical parameters and the haplotypes (T-G-4b (rs2070744- rs1799983-intron
4 VNTR)/T-G-4b, T-G-4b/other e other/other) at eNOS gene
Parameters T-G-4b/T-G-4b T-G-4b/Other Other/Other p-value
Total Hb (g/dL) 8.90 ± 1.49 (4) 8.60 ± 1.38 (15) 8.42 ± 0.98 (4) 0.8801
Hb S (%) 74.15 ± 3.87 (4) 75.31 ± 7.10 (14) 73.67 ± 8.26 (4) 0.8971
Total bilirubin (mg/dL) 1.45; 1.26–1.65 (2) 1.94; 1.30–5.57 (8) 3.42; 1.39–5.46 (2) 0.3222
LDH (U/L) 463.00; 410.00–516.00 (2) 451.00; 332.00–793.00 (7) 409.00; 328.00–490.00 (2) 0.7692
RDW (%) 21.00 ± 1.55 (2) 22.01 ± 2.60 (7) 23.80 (1) 0.6701
Reticulocyte count (%) 8.91 ± 5.18 (4) 7.28 ± 3.09 (15) 10.15 ± 2.60 (4) 0.3081
Levels of leukocytes 8600.00; 10500.00; 16800.00 (1) 0.1492
(cell/L) 7000.00–10200.00 (2) 9800.00–33100.00 (7)
Levels of neutrophils 2535.00 ± 1350.57 (2) 5652.14 ± 1880.28 (7) 6380.00 (1) 0.1451
(cell/L)
ACP1 (mol/g Hb/h) 399.10 ± 9.03 (2) 382.10 ± 114.23 (10) 270.58 ± 29.57 (2) 0.4001
MPO (ng/mL) 26.11 ± 0.39 (2) 41.11 ± 19.41 (9) 34.01 ± 23.00 (3) 0.5881
MetHbR (mol/g Hb/min) 27.65 (1) 25.38 ± 9.77 (10) 14.98 ± 3.65 (2) 0.3651
TMR (mmol/lcell/h) 4.71 (1) 5.31 ± 1.23 (3) (0) 0.7131
1ANOVA test - Mean ± standard deviation (n – sample size). 2Kruskal-Wallis test - Median; minimum - maximum
(n – sample size).
association of the a allele with higher number of neutrophils may be related with eNOS haplotypes,
instead of eNOS genotypes alone. In fact, that has been suggested in other studies [13, 22]. However
we did not observe statistically significant differences once analyzing haplotypes, probably because
of the low sample size.
Our results reinforce the importance of NO bioactivity in SCA. We presume that NO, and its
precursors might be used as therapy to improve the quality of life of SCA patients.
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